CEIB - Centre Interfacultaire des Biomatériaux - ULiège
Disciplines :
Ingénierie, informatique & technologie: Multidisciplinaire, généralités & autres
Auteur, co-auteur :
Marques, J.
Valle-Delgado, J.
Urbán, P.
Baró, E.
Prohens, R.
Mayo, A.
Cisteró, P.
Delves, M.
Sinden, R.
Grandfils, Christian ; Université de Liège > Département des sciences biomédicales et précliniques > Biochimie et physiologie générales, et biochimie humaine
1 Prudêncio, M., Rodriguez, A., Mota, M.M., The silent path to thousands of merozoites: the Plasmodium liver stage. Nat Rev Microbiol 4:11 (2006), 849–856.
2 Cowman, A.F., Crabb, B.S., Invasion of red blood cells by malaria parasites. Cell 124:4 (2006), 755–766.
3 Alonso, P.L., Tanner, M., Public health challenges and prospects for malaria control and elimination. Nat Med 19:2 (2013), 150–155.
4 Urbán, P., Valle-Delgado, J.J., Moles, E., Marques, J., Díez, C., Fernàndez-Busquets, X., Nanotools for the delivery of antimicrobial peptides. Curr Drug Targets 13:9 (2012), 1158–1172.
5 Urbán, P., Fernàndez-Busquets, X., Nanomedicine against malaria. Curr Med Chem 21:5 (2014), 605–629.
6 Kuntworbe, N., Martini, N., Shaw, J., Al-Kassas, R., Malaria intervention policies and pharmaceutical nanotechnology as a potential tool for malaria management. Drug Dev Res 73 (2012), 167–184.
7 Baird, J.K., Effectiveness of antimalarial drugs. N Engl J Med 352:15 (2005), 1565–1577.
8 Moles, E., Urbán, P., Jiménez-Díaz, M.B., Viera-Morilla, S., Angulo-Barturen, I., Busquets, M.A., et al. Immunoliposome-mediated drug delivery to Plasmodium-infected and non-infected red blood cells as a dual therapeutic/prophylactic antimalarial strategy. J Control Release 210 (2015), 217–229.
9 Burrows, J., van Huijsduijnen, H.R, Möhrle, J., Oeuvray, C., Wells, T., Designing the next generation of medicines for malaria control and eradication. Malar J, 12(1), 2013, 187.
10 Fried, M., Duffy, P.E., Adherence of Plasmodium falciparum to chondroitin sulfate A in the human placenta. Science 272:5267 (1996), 1502–1504.
11 Andrews, K.T., Klatt, N., Adams, Y., Mischnick, P., Schwartz-Albiez, R., Inhibition of chondroitin-4-sulfate-specific adhesion of Plasmodium falciparum-infected erythrocytes by sulfated polysaccharides. Infect Immun 73:7 (2005), 4288–4294.
12 Baruch, D.I., Gormley, J.A., Ma, C., Howard, R.J., Pasloske, B.L., Plasmodium falciparum erythrocyte membrane protein 1 is a parasitized erythrocyte receptor for adherence to CD36, thrombospondin, and intercellular adhesion molecule 1. Proc Natl Acad Sci U S A 93:8 (1996), 3497–3502.
13 Reeder, J.C., Cowman, A.F., Davern, K.M., Beeson, J.G., Thompson, J.K., Rogerson, S.J., et al. The adhesion of Plasmodium falciparum-infected erythrocytes to chondroitin sulfate A is mediated by P. falciparum erythrocyte membrane protein 1. Proc Natl Acad Sci U S A 96:9 (1999), 5198–5202.
14 Valle-Delgado, J.J., Urbán, P., Fernàndez-Busquets, X., Demonstration of specific binding of heparin to Plasmodium falciparum-infected vs non-infected red blood cells by single-molecule force spectroscopy. Nanoscale 5:9 (2013), 3673–3680.
15 Sheehy, T.W., Reba, R.C., Complications of falciparum malaria and their treatment. Ann Intern Med 66:4 (1967), 807–809.
16 Marques, J., Moles, E., Urbán, P., Prohens, R., Busquets, M.A., Sevrin, C., et al. Application of heparin as a dual agent with antimalarial and liposome targeting activities towards Plasmodium-infected red blood cells. Nanomedicine: NBM 10 (2014), 1719–1728.
17 Sinden, R., Carter, R., Drakeley, C., Leroy, D., The biology of sexual development of Plasmodium: the design and implementation of transmission-blocking strategies. Malar J, 11(1), 2012, 70.
18 Ancsin, J.B., Kisilevsky, R., A binding site for highly sulfated heparan sulfate is identified in the N terminus of the circumsporozoite protein: significance for malarial sporozoite attachment to hepatocytes. J Biol Chem 279:21 (2004), 21824–21832.
19 Dinglasan, R.R., Alaganan, A., Ghosh, A.K., Saito, A., van Kuppevelt, T.H., Jacobs-Lorena, M., Plasmodium falciparum ookinetes require mosquito midgut chondroitin sulfate proteoglycans for cell invasion. Proc Natl Acad Sci U S A 104:40 (2007), 15882–15887.
20 Mathias, D.K., Pastrana-Mena, R., Ranucci, E., Tao, D., Ferruti, P., Ortega, C., et al. A small molecule glycosaminoglycan mimetic blocks Plasmodium invasion of the mosquito midgut. PLoS Pathog, 9(11), 2013, e1003757.
21 Li, F., Templeton, T.J., Popov, V., Comer, J.E., Tsuboi, T., Torii, M., et al. Plasmodium ookinete-secreted proteins secreted through a common micronemal pathway are targets of blocking malaria transmission. J Biol Chem 279:25 (2004), 26635–26644.
22 MacDonald, R.C., MacDonald, R.I., Menco, B.P., Takeshita, K., Subbarao, N.K., Hu, L.R., Small-volume extrusion apparatus for preparation of large, unilamellar vesicles. Biochim Biophys Acta 1061:2 (1991), 297–303.
23 Urbán, P., Estelrich, J., Cortés, A., Fernàndez-Busquets, X., A nanovector with complete discrimination for targeted delivery to Plasmodium falciparum-infected versus non-infected red blood cells in vitro. J Control Release 151:2 (2011), 202–211.
24 Frazier, S.B., Roodhouse, K.A., Hourcade, D.E., Zhang, L., The quantification of glycosaminoglycans: a comparison of HPLC, carbazole, and Alcian Blue methods. Open Glycosci 1 (2008), 31–39.
25 Arias, J.L., López-Viota, M., Gallardo, V., Ruiz, M.A., Chitosan nanoparticles as a new delivery system for the chemotherapy agent tegafur. Drug Dev Ind Pharm 36:6 (2010), 744–750.
26 O'Brien, R.W., White, L.R., Electrophoretic mobility of a spherical colloidal particle. J Chem Soc Faraday Trans 2 74 (1978), 1607–1626.
27 Cranmer, S.L., Magowan, C., Liang, J., Coppel, R.L., Cooke, B.M., An alternative to serum for cultivation of Plasmodium falciparum in vitro. Trans R Soc Trop Med Hyg 91:3 (1997), 363–365.
28 Han, Z.R., Wang, Y.F., Liu, X., Wu, J.D., Cao, H., Zhao, X., et al. Fluorescent labeling of several glycosaminoglycans and their interaction with anti-chondroitin sulfate antibody. Chin J Anal Chem 39:9 (2011), 1352–1357.
29 Urbán, P., Valle-Delgado, J.J., Mauro, N., Marques, J., Manfredi, A., Rottmann, M., et al. Use of poly(amidoamine) drug conjugates for the delivery of antimalarials to Plasmodium. J Control Release 177 (2014), 84–95.
30 Kirk, K., Membrane transport in the malaria-infected erythrocyte. Physiol Rev 81:2 (2001), 495–537.
31 Goodyer, I.D., Pouvelle, B., Schneider, T.G., Trelka, D.P., Taraschi, T.F., Characterization of macromolecular transport pathways in malaria-infected erythrocytes. Mol Biochem Parasitol 87:1 (1997), 13–28.
32 Fernàndez-Busquets, X., Heparin-functionalized nanocapsules: enabling targeted delivery of antimalarial drugs. Future Med Chem 5:7 (2013), 737–739.
33 Beutler, E., Duparc, S., Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. Am J Trop Med Hyg 77:4 (2007), 779–789.
34 Burgoine, K.L., Bancone, G., Nosten, F., The reality of using primaquine. Malar J, 9(1), 2010, 376.
35 Chan, T.K., Todd, D., Tso, S.C., Drug-induced haemolysis in glucose-6-phosphate dehydrogenase deficiency. Br Med J 2 (1976), 1227–1229.
36 Miura, Y., Aoyagi, S., Kusada, Y., Miyamoto, K., The characteristics of anticoagulation by covalently immobilized heparin. J Biomed Mater Res 14:5 (1980), 619–630.
37 Leitgeb, A.M., Blomqvist, K., Cho-Ngwa, F., Samje, M., Nde, P., Titanji, V., et al. Low anticoagulant heparin disrupts Plasmodium falciparum rosettes in fresh clinical isolates. Am J Trop Med Hyg 84:3 (2011), 390–396.
38 Vogt, A.M., Pettersson, F., Moll, K., Jonsson, C., Normark, J., Ribacke, U., et al. Release of sequestered malaria parasites upon injection of a glycosaminoglycan. PLoS Pathog, 2(9), 2006, e100.
39 Linhardt, R.J., Rice, K.G., Kim, Y.S., Engelken, J.D., Weiler, J.M., Homogeneous, structurally defined heparin-oligosaccharides with low anticoagulant activity inhibit the generation of the amplification pathway C3 convertase in vitro. J Biol Chem 263:26 (1988), 13090–13096.
40 Baldrick, P., The safety of chitosan as a pharmaceutical excipient. Regul Toxicol Pharmacol 56:3 (2010), 290–299.
41 Kean, T., Thanou, M., Biodegradation, biodistribution and toxicity of chitosan. Adv Drug Deliv Rev 62:1 (2010), 3–11.
42 Sinha, V.R., Singla, A.K., Wadhawan, S., Kaushik, R., Kumria, R., Bansal, K., et al. Chitosan microspheres as a potential carrier for drugs. Int J Pharm 274:1-2 (2004), 1–33.
43 Smitskamp, H., Wolthuis, F.H., New concepts in treatment of malignant tertian malaria with cerebral involvement. Br Med J 1 (1971), 714–716.
45 Munir, M., Tjandra, H., Rampengan, T.H., Mustadjab, I., Wulur, F.H., Heparin in the treatment of cerebral malaria. Paediatr Indones 20 (1980), 47–50.
46 World Health Organization Malaria Action Programme, Severe and complicated malaria. Trans R Soc Trop Med Hyg 80:Suppl (1986), 3–50.
47 Marques, J., Vilanova, E., Mourão, P.A.S., Fernàndez-Busquets, X., Marine organism sulfated polysaccharides exhibiting significant antimalarial activity and inhibition of red blood cell invasion by Plasmodium. Sci Rep, 6, 2016, 24368.
48 Bell, G.I., Models for the specific adhesion of cells to cells. Science 200 (1978), 618–627.
49 Evans, E., Ritchie, K., Dynamic strength of molecular adhesion bonds. Biophys J 72:4 (1997), 1541–1555.
50 Carvalho, P.A., Diez-Silva, M., Chen, H., Dao, M., Suresh, S., Cytoadherence of erythrocytes invaded by Plasmodium falciparum: quantitative contact-probing of a human malaria receptor. Acta Biomater 9:5 (2013), 6349–6359.
51 Adams, Y., Freeman, C., Schwartz-Albiez, R., Ferro, V., Parish, C.R., Andrews, K.T., Inhibition of Plasmodium falciparum growth in vitro and adhesion to chondroitin-4-sulfate by the heparan sulfate mimetic PI-88 and other sulfated oligosaccharides. Antimicrob Agents Chemother 50:8 (2006), 2850–2852.
52 Santos-Magalhães, N.S., Mosqueira, V.C.F., Nanotechnology applied to the treatment of malaria. Adv Drug Deliv Rev 62:4-5 (2010), 560–575.
53 Mosqueira, V.C.F., Loiseau, P.M., Bories, C., Legrand, P., Devissaguet, J.P., Barratt, G., Efficacy and pharmacokinetics of intravenous nanocapsule formulations of halofantrine in Plasmodium berghei-infected mice. Antimicrob Agents Chemother 48:4 (2004), 1222–1228.
54 Murambiwa, P., Masola, B., Govender, T., Mukaratirwa, S., Musabayane, C.T., Anti-malarial drug formulations and novel delivery systems: a review. Acta Trop 118:2 (2011), 71–79.
55 Boyle, M.J., Richards, J.S., Gilson, P.R., Chai, W., Beeson, J.G., Interactions with heparin-like molecules during erythrocyte invasion by Plasmodium falciparum merozoites. Blood 115:22 (2010), 4559–4568.
56 Kyes, S., Horrocks, P., Newbold, C., Antigenic variation at the infected red cell surface in malaria. Annu Rev Microbiol 55 (2001), 673–707.
57 Duffy, M.F., Maier, A.G., Byrne, T.J., Marty, A.J., Elliott, S.R., O'Neill, M.T., et al. VAR2CSA is the principal ligand for chondroitin sulfate A in two allogeneic isolates of Plasmodium falciparum. Mol Biochem Parasitol 148:2 (2006), 117–124.
58 Chaccour, C., Kobylinski, K., Bassat, Q., Bousema, T., Drakeley, C., Alonso, P., et al. Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for elimination. Malar J, 12(1), 2013, 153.
59 Alphey, L., Andreasen, M., Dominant lethality and insect population control. Mol Biochem Parasitol 121:2 (2002), 173–178.
60 Andreasen, M.H., Curtis, C.F., Optimal life stage for radiation sterilization of Anopheles males and their fitness for release. Med Vet Entomol 19:3 (2005), 238–244.
